OSUR on XNAS, Health Care, OraSure Technologies Inc, job postings
Measures activity, not value. Not investment advice.
Quarterly revenue rose 14% and shares are up 64% in a year, but twelve-month revenue fell 7.5%.
BadFree cash flow was negative $49.6M over 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $30.9M, net loss $13.1M.
31 Dec 2021RevenueNet incomeNet losstallest bar $155.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$30.9M
-$13.1M
30 Jun 2026
$30.6M
$6.2M
31 Mar 2026
$27.9M
-$22.4M
31 Dec 2025
$26.8M
-$19.3M
30 Sep 2025
$27.1M
-$13.7M
30 Jun 2025
$31.2M
-$19.7M
31 Mar 2025
$29.9M
-$16.0M
31 Dec 2024
$37.4M
–
30 Sep 2024
$39.9M
-$4.5M
30 Jun 2024
$54.3M
-$615K
31 Mar 2024
$54.1M
-$3.6M
31 Dec 2023
$75.9M
–
30 Sep 2023
$89.2M
$11.2M
30 Jun 2023
$85.4M
-$4.8M
31 Mar 2023
$155.0M
$27.2M
31 Dec 2022
$123.1M
$15.6M
30 Sep 2022
$116.5M
$5.3M
30 Jun 2022
$80.2M
-$18.8M
31 Mar 2022
$67.7M
-$20.0M
31 Dec 2021
$63.6M
-$10.4M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$116.2M
$125.7M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-7.5%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$48.5M
-$60.2M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.69
-$0.80
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
43.1%
40.4%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-43.8%
-51.1%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-41.7%
-47.9%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-14.5%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$49.6M
-$43.6M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$148.2M
$216.5M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$148.2M (net cash)
-$216.5M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$4.45
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.1
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
0.78
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.78
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+14%
$30.9M vs $27.1M (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-2.0%
146 13F filers vs 149
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
82%
56.9M shares held by 13F filers (30 Sep 2026) of 69.0M outstanding (2 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
3.8%
2.6M shares sold short (30 Oct 2026) of 69.0M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.6
2.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-4.3%
2.7M shares sold short in the report before, 2.6M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
65%
65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 45%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
3
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$388K
the 12 months before: $174K
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$10K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
5
5 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.0×
5 articles in the last 7 days; its usual week has 1.
Price $3.46 on 20 Nov 2026, +64% over 12 months (12-month range $2.11 to $4.50)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $551K in the last 12 months (the 12 months before: $761K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 3 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $30.9M in the latest quarter, +14% on a year earlier.Capital spending per quarter. Capital spending $1.7M in the latest quarter, +82% on a year earlier.Institutional holders (13F filers). 146 13F filers reported holding it in the latest 13F quarter, +5.0% on a year earlier.Federal obligations. Federal obligations: $293K published in the last 12 months, +23% on the 12 months before.Lobbying spend. Lobbying spend: $10K published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $63.6M, +1.1% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $67.7M, +16% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $80.2M, +39% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $116.5M, +116% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $123.1M, +94% on a year earlier; public on 4 Mar 2023
Quarter ended 31 Mar 2023: $155.0M, +129% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $85.4M, +6.5% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $89.2M, -23% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $75.9M, -38% on a year earlier; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $54.1M, -65% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $54.3M, -36% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $39.9M, -55% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $37.4M, -51% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $29.9M, -45% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $31.2M, -43% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $27.1M, -32% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $26.8M, -29% on a year earlier; public on 10 Mar 2026
Quarter ended 31 Mar 2026: $27.9M, -6.7% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $30.6M, -1.9% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $30.9M, +14% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $9.1M, -41% on a year earlier; public on 2 Mar 2022
Quarter ended 30 Jun 2022: $5.2M, -56% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $2.6M, -42% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Mar 2023: $1.2M; public on 11 May 2023
Quarter ended 30 Jun 2023: $1.7M, -67% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $1.6M, -39% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Mar 2024: $1.6M, +33% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $1.6M, -5.0% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $145K, -91% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $456K; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $420K, -73% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $1.9M, +20% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $919K, +534% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $922K, +102% on a year earlier; public on 10 Mar 2026
Quarter ended 31 Mar 2026: $913K, +117% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $2.4M, +25% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $1.7M, +82% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 170; public on 14 Feb 2022
31 Mar 2022 report: 175; public on 16 May 2022
30 Jun 2022 report: 178; public on 15 Aug 2022
30 Sep 2022 report: 173; public on 14 Nov 2022
31 Dec 2022 report: 177; public on 14 Feb 2023
31 Mar 2023 report: 189; public on 15 May 2023
30 Jun 2023 report: 191; public on 14 Aug 2023
30 Sep 2023 report: 197; public on 14 Nov 2023
31 Dec 2023 report: 209; public on 14 Feb 2024
31 Mar 2024 report: 224; public on 15 May 2024
30 Jun 2024 report: 196; public on 14 Aug 2024
30 Sep 2024 report: 182; public on 14 Nov 2024
31 Dec 2024 report: 187; public on 14 Feb 2025
31 Mar 2025 report: 174; public on 15 May 2025
30 Jun 2025 report: 150; public on 14 Aug 2025
30 Sep 2025 report: 139; public on 14 Nov 2025
31 Dec 2025 report: 134; public on 17 Feb 2026
31 Mar 2026 report: 134; public on 15 May 2026
30 Jun 2026 report: 149; public on 14 Aug 2026
30 Sep 2026 report: 146; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $165.4M published
Month from 1 Jan 2022: $388.6M published
Month from 1 Feb 2022: $1.0M published
Month from 1 Mar 2022: $2.8M published
Month from 1 Apr 2022: $5.3M published
Month from 1 May 2022: $3.0M published
Month from 1 Jun 2022: $520 published
Month from 1 Jul 2022: $115 published
Month from 1 Aug 2022: $11K published
Month from 1 Sep 2022: $396K published
Month from 1 Oct 2022: $8.6M published
Month from 1 Nov 2022: $1K published
Month from 1 Dec 2022: $10.5M published
Month from 1 Jan 2023: $635 published
Month from 1 Feb 2023: $500 published
Month from 1 Mar 2023: $53.6M published
Month from 1 Apr 2023: $30.9M published
Month from 1 May 2023: $0 published
Month from 1 Jun 2023: $444 published
Month from 1 Jul 2023: -$1K published
Month from 1 Aug 2023: -$30.9M published
Month from 1 Sep 2023: $12.6M published
Month from 1 Nov 2023: $390 published
Month from 1 Dec 2023: $1K published
Month from 1 Jan 2024: $830 published
Month from 1 Feb 2024: $250 published
Month from 1 Apr 2024: -$6.5M published
Month from 1 May 2024: -$326 published
Month from 1 Jun 2024: $415 published
Month from 1 Jul 2024: -$500 published
Month from 1 Aug 2024: -$65K published
Month from 1 Sep 2024: $239K published
Month from 1 Oct 2024: -$825 published
Month from 1 Nov 2024: $0 published
Month from 1 Dec 2024: -$351 published
Month from 1 Jan 2025: $0 published
Month from 1 Feb 2025: $449 published
Month from 1 Mar 2025: $0 published
Month from 1 May 2025: $50.0 published
Month from 1 Jun 2025: $75.0 published
Month from 1 Aug 2025: $125 published
Month from 1 Sep 2025: $239K published
Month from 1 Nov 2025: -$665 published
Month from 1 Dec 2025: -$275 published
Month from 1 Feb 2026: -$2K published
Month from 1 May 2026: -$39K published
Month from 1 Jun 2026: $239K published
Month from 1 Jul 2026: -$47K published
Month from 1 Aug 2026: $143K published
Lobbying spend
Quarter from 1 Jan 2022: $10K published
Quarter from 1 Apr 2022: $50K published
Quarter from 1 Jul 2022: $50K published
Quarter from 1 Oct 2022: $10K published
Quarter from 1 Jan 2023: $10K published
Quarter from 1 Apr 2023: $10K published
Quarter from 1 Oct 2026: $10K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $225K (14 May 2026), 2.4× its normal reading; higher than 96% of its own history.
Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response
$8.6M
THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A
Reported lobbying spend: $10K in Q3 2026, $10K in Q1 2023. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Jul 2022
Ended
Crossroads Strategies, LLCfor Sense Biodetection Ltd.
Two or more unrelated kinds of records unusual within 30 days
16 May 2023confirmed
Confirmed across sources Government contracts and Filings + Financials
OraSure Technologies(OSUR): booked $30.9M in federal contract and grant obligations in April 2023, 268,557× the same month last year, while it reported revenue of $155.0M for the quarter ended 31 Mar 2023, 2.3× the same quarter last year. Two unrelated kinds of activity within 7 days.
Government contracts: Federal obligations jump, became public on 4 May 2023
Financials: Quarterly revenue change, became public on 16 May 2023
April 2023 against the 5 months before it.
this monthearliernormal: $20KSee the evidence (2 changes)
Government contracts: Federal obligations jump became public on 4 May 2023
OraSure Technologies booked $30.9M in federal contract and grant obligations in April 2023, 268,557× the same month last year.
This period
$30.9M (April 2023)
Normal month (median of 5 earlier)
$20K
Typical spread (median absolute deviation)
$20K
How far from its usual level
+30.9
Same month last year
$115
History used
5,689 days
April 20235 earlier monthsnormal: $20K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 16 May 2023
OraSure Technologies reported revenue of $155.0M for the quarter ended 31 Mar 2023, 2.3× the same quarter last year.
This period
$155.0M (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
$65.6M
Typical spread (median absolute deviation)
$9.9M
How far from its usual level
+6.1
Same quarter last year
$67.7M
History used
4,657 days
the quarter ended 31 Mar 20238 earlier quartersnormal: $65.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 3.3M shares sold short in the 15 Dec 2023 report, 2.0× the same report last year.
Same report last year: 1.6M; its normal report is 1.6M.
See the evidence
This period
3.3M (the 15 Dec 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
306K
How far from its usual level
+3.7
Same report last year
1.6M
History used
2,177 days
the 15 Dec 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.1M shares sold short in the 30 Nov 2023 report, 2.1× the same report last year.
Same report last year: 1.5M; its normal report is 1.6M.
See the evidence
This period
3.1M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
268K
How far from its usual level
+3.9
Same report last year
1.5M
History used
2,162 days
the 30 Nov 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.3M shares sold short in the 15 Nov 2023 report, 1.9× the same report last year.
Same report last year: 1.7M; its normal report is 1.6M.
See the evidence
This period
3.3M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
234K
How far from its usual level
+4.9
Same report last year
1.7M
History used
2,147 days
the 15 Nov 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.9M shares sold short in the 31 Oct 2023 report, 1.5× the same report last year.
Same report last year: 2.0M; its normal report is 1.6M.
See the evidence
This period
2.9M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
234K
How far from its usual level
+3.8
Same report last year
2.0M
History used
2,132 days
the 31 Oct 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
booked $30.9M in federal contract and grant obligations in April 2023, 268,557× the same month last year, while it reported revenue of $155.0M for the quarter ended 31 Mar 2023, 2.3× the same quarter last year. Two unrelated kinds of activity within 7 days.
See the evidence (2 changes)
Government contracts: Federal obligations jump became public on 4 May 2023
OraSure Technologies booked $30.9M in federal contract and grant obligations in April 2023, 268,557× the same month last year.
This period
$30.9M (April 2023)
Normal month (median of 5 earlier)
$20K
Typical spread (median absolute deviation)
$20K
How far from its usual level
+30.9
Same month last year
$115
History used
5,689 days
April 20235 earlier monthsnormal: $20K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 16 May 2023
OraSure Technologies reported revenue of $155.0M for the quarter ended 31 Mar 2023, 2.3× the same quarter last year.
This period
$155.0M (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
$65.6M
Typical spread (median absolute deviation)
$9.9M
How far from its usual level
+6.1
Same quarter last year
$67.7M
History used
4,657 days
the quarter ended 31 Mar 20238 earlier quartersnormal: $65.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 May 2023Financials change
reported revenue of $155.0M for the quarter ended 31 Mar 2023, 2.3× the same quarter last year.
Same quarter last year: $67.7M; its normal quarter is $65.6M.
See the evidence
This period
$155.0M (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
$65.6M
Typical spread (median absolute deviation)
$9.9M
How far from its usual level
+6.1
Same quarter last year
$67.7M
History used
4,657 days
the quarter ended 31 Mar 20238 earlier quartersnormal: $65.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
booked $30.9M in federal contract and grant obligations in April 2023, 268,557× the same month last year.
Same month last year: $115; its normal month is $20K.
See the evidence
This period
$30.9M (April 2023)
Normal month (median of 5 earlier)
$20K
Typical spread (median absolute deviation)
$20K
How far from its usual level
+30.9
Same month last year
$115
History used
5,689 days
April 20235 earlier monthsnormal: $20K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Showing the newest 40 of 134 entries; narrow the window or the kind of data to see older ones.
Not listed: 167 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001116463
Ticker
OSUR
Domain
orasure.com
Employer name
ORASURE TECHNOLOGIES, INC. (1 unverified)
Hq location
PA|BETHLEHEM|18015 (1 unverified)
Lobbying client
orasure technologies, sense biodetection
Name
BioMedomics, Inc, DNA Genotek Inc, OraSure Technologies Inc, Sense Biodetection Limited and 1 more
Uei
HGF7SBHLMRD9, Y79RWFLHWDM6
Wikipedia
OraSure Technologies
DOL H-1B labor condition applications and PERM certifications40 data points12 Oct 2020 to 14 Sep 2026
Federal lobbying disclosures (LDA)7 records, 231 data points15 Nov 2000 to 30 Sep 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)166 records3 Feb 2016 to 9 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1194 data points31 Dec 2008 to 2 Nov 2026
SEC Form 4 insider transactions75 records, 188 data points31 Aug 2016 to 14 May 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards14 records, 1839 data points2 Oct 2007 to 17 Aug 2026
Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026